MX2023013096A - Uso farmaceutico de compuesto de peptidos ciclicos. - Google Patents

Uso farmaceutico de compuesto de peptidos ciclicos.

Info

Publication number
MX2023013096A
MX2023013096A MX2023013096A MX2023013096A MX2023013096A MX 2023013096 A MX2023013096 A MX 2023013096A MX 2023013096 A MX2023013096 A MX 2023013096A MX 2023013096 A MX2023013096 A MX 2023013096A MX 2023013096 A MX2023013096 A MX 2023013096A
Authority
MX
Mexico
Prior art keywords
cyclic peptide
peptide compound
pharmaceutical use
compound
cyclic
Prior art date
Application number
MX2023013096A
Other languages
English (en)
Inventor
Atsushi Matsuo
Mikimasa Tanada
Koji Takano
Minoru Tamiya
Aya Chiyoda
Toshiya Ito
Takeo Iida
Atsushi Ohta
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2023013096A publication Critical patent/MX2023013096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los presentes inventores encontraron compuestos de péptidos cíclicos que interactúan con Ras, y composiciones farmacéuticas que contienen los compuestos de péptidos cíclicos o sus sales, o sus solvatos.
MX2023013096A 2021-05-07 2022-05-06 Uso farmaceutico de compuesto de peptidos ciclicos. MX2023013096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079013 2021-05-07
PCT/JP2022/019542 WO2022234852A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物の医薬用途

Publications (1)

Publication Number Publication Date
MX2023013096A true MX2023013096A (es) 2023-11-16

Family

ID=83932764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013096A MX2023013096A (es) 2021-05-07 2022-05-06 Uso farmaceutico de compuesto de peptidos ciclicos.

Country Status (12)

Country Link
US (1) US20240148821A1 (es)
EP (1) EP4316503A1 (es)
JP (2) JP7179241B1 (es)
KR (2) KR102666765B1 (es)
CN (1) CN117279655A (es)
AU (1) AU2022270499A1 (es)
BR (1) BR112023022875A2 (es)
CA (1) CA3219415A1 (es)
IL (1) IL307635A (es)
MX (1) MX2023013096A (es)
TW (1) TW202309064A (es)
WO (1) WO2022234852A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214576A1 (ja) * 2022-05-06 2023-11-09 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
WO2024085235A1 (ja) * 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法
WO2024101386A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
JP2024069167A (ja) * 2022-11-09 2024-05-21 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物を含む医薬組成物
WO2024111590A1 (ja) * 2022-11-22 2024-05-30 一丸ファルコス株式会社 Ｒａｓ阻害ペプチドを含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6239979B2 (ja) 2011-03-04 2017-11-29 ニューヨーク・ユニバーシティ Ｒａｓの調節因子としての水素結合代替大環状分子
TWI640541B (zh) 2011-12-28 2018-11-11 中外製藥股份有限公司 Peptide compound having an annular portion and pharmaceutical composition thereof
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN110869544B (zh) 2017-06-09 2024-03-08 中外制药株式会社 膜透过性高的环状肽化合物及包含其的文库
KR20230169447A (ko) * 2017-06-09 2023-12-15 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
SG10202111127YA (en) * 2019-11-07 2021-11-29 Chugai Pharmaceutical Co Ltd Cyclic Peptide Compound Having Kras Inhibitory Action

Also Published As

Publication number Publication date
US20240148821A1 (en) 2024-05-09
TW202309064A (zh) 2023-03-01
KR102666765B1 (ko) 2024-05-16
JPWO2022234852A1 (es) 2022-11-10
BR112023022875A2 (pt) 2024-01-23
JP7179241B1 (ja) 2022-11-28
AU2022270499A1 (en) 2023-11-23
IL307635A (en) 2023-12-01
CA3219415A1 (en) 2022-11-10
KR20230017916A (ko) 2023-02-06
KR20240074875A (ko) 2024-05-28
WO2022234852A1 (ja) 2022-11-10
JP2023001389A (ja) 2023-01-04
EP4316503A1 (en) 2024-02-07
CN117279655A (zh) 2023-12-22

Similar Documents

Publication Publication Date Title
MX2023013096A (es) Uso farmaceutico de compuesto de peptidos ciclicos.
PH12019500579A1 (en) Pharmaceutical composition
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
NZ763551A (en) Compounds useful for inhibiting cdk7
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PH12021550713A1 (en) Medicament for the treatment of chronic cough
BR112018074985A2 (pt) composições antibacterianas
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2021014680A (es) Derivado de benzotriazol.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2021005944A (es) Inhibidores de rip1.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX2021003830A (es) Uso terapéutico del glucagón y combinación que incluye el mismo.
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
TR201722367A2 (tr) Lakozami̇d i̇çeren parenteral uygulmaya yöneli̇k farmasöti̇k kompozi̇syonlar
EP4088731A4 (en) COMPOSITION CONTAINING A PEPTIDE OR PEPTIDE COMPOUND USED AS ACTIVE INGREDIENT, AND ITS MEDICAL USE